| 2026-08-04 | 10-Q | 10.2 | Form of Performance Stock Unit Agreement under the 2023 Omnibus Incentive Plan. |
|---|
| 2026-08-04 | 10-Q | 10.1 | Amendment No. 3 to Precigen, Inc. 2023 Omnibus Incentive Plan. |
|---|
| 2026-03-25 | 10-K | 10.7 | Precigen, Inc. 2023 Omnibus Incentive Plan (10) Amendment No.1 to Precigen, Inc. 2023 Omnibus Incentive Plan Amendment No.2 to Precigen, Inc. 2023 Omnibus Incentive Plan |
|---|
| 2026-03-25 | 10-K | 10.7 | Precigen, Inc. 2023 Omnibus Incentive Plan (10) Amendment No.1 to Precigen, Inc. 2023 Omnibus Incentive Plan Amendment No.2 to Precigen, Inc. 2023 Omnibus Incentive Plan |
|---|
| 2026-03-25 | 10-K | 10.2 | 2019 Incentive Plan of the Company for Non-Employee Service Providers, effective as of June 12, 2019 (9) Amendment No.1 to Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers Amendment No.2 to Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers |
|---|
| 2026-03-25 | 10-K | 10.2 | 2019 Incentive Plan of the Company for Non-Employee Service Providers, effective as of June 12, 2019 (9) Amendment No.1 to Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers Amendment No.2 to Precigen, Inc. 2019 Incentive Plan for Non-Employee Service Providers |
|---|
| 2025-09-03 | 8-K | 10.1 | Loan Agreement dated as of September 3, 2025, among Precigen, Inc., the guarantors signatory thereto, Biopharma Credit PLC as Collateral Agent, BPCR Limited Partnership and Biopharma Credit Investments V (Master) LP as Lenders |
|---|
| 2025-08-18 | 8-K | 10.1 | Commercial Supply Agreement, dated August 13, 2025, by and between Precigen, Inc. and Catalent Maryland, Inc. |
|---|
| 2025-03-19 | 10-K | 10.15 | Product Commercialization Agreement with EVERSANA Life Science Services, LLC, dated March 19, 2025 |
|---|
| 2024-12-30 | 8-K | 10.3 | Form of Common Stock Purchase Warrant. |
|---|
| 2024-12-30 | 8-K | 10.2 | Registration Rights Agreement, dated December 30, 2024 between Precigen Inc. and the Investors party thereto. |
|---|
| 2024-12-30 | 8-K | 10.1 | Securities Purchase Agreement, dated December 27, 2024 between Precigen Inc. and the Investors party thereto. |
|---|
| 2024-11-14 | 10-Q | 10.1 | Form of Performance Stock Unit Agreement under the 2023 Omnibus Incentive Plan. |
|---|
| 2024-03-19 | 10-K | 10.11 | Form of Continuing Employment Agreement (2024) |
|---|
| 2024-03-19 | 10-K | 10.10 | Form of Incentive Stock Option Agreement under the 2023 Omnibus Incentive Plan |
|---|
| 2024-03-19 | 10-K | 10.9 | Form of Restricted Stock Unit Agreement under the 2023 Omnibus Incentive Plan |
|---|
| 2023-08-09 | 10-Q | 10.1 | Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, dated April 3, 2023. |
|---|
| 2023-05-10 | 10-Q | 10.1 | Amended and Restated Exclusive License Agreement with Alaunos Therapeutics, dated April 3, 2023. |
|---|
| 2020-11-09 | 10-Q | 10.1 | Executive Chairman Compensation Arrangement, by and between the Company and Randal J. Kirk. |
|---|
| 2020-06-19 | 8-K | 10.1 | Amendment to the Precigen, Inc. Amended and Restated 2013 Omnibus Incentive Plan, as amended, effective as of June 19, 2020. |
|---|
| 2020-05-11 | 10-Q | 10.1 | Amendment to the Amended and Restated 2013 Omnibus Incentive Plan of the Company, as amended, effective as of January 5, 2020. |
|---|
| 2020-01-07 | 8-K | 10.1 | Employment Agreement, dated January 1, 2020, by and between Intrexon Corporation and Helen Sabzevari, Ph.D. |
|---|
| 2020-01-02 | 8-K | 10.2 | Subscription Agreement, dated January 1, 2019, by and between Intrexon Corporation and Third Security, LLC. |
|---|
| 2020-01-02 | 8-K | 10.1 | Stock and Asset Purchase Agreement, dated January 1, 2019, by and between Intrexon Corporation and Third Security, LLC. |
|---|
| 2019-10-31 | 8-K | 10.1 | Stock Purchase Agreement, dated October 29, 2019 by and between Intrexon Corporation and TS AquaCulture LLC |
|---|
| 2019-08-09 | 10-Q | 10.5 | Intrexon Corporation 2019 Incentive Plan for Non-Employee Service Providers, effective as of June 12, 2019. |
|---|
| 2019-06-12 | 8-K | 10.1 | Amendment to the Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, as amended, effective as of June 12, 2019. |
|---|
| 2019-05-09 | 10-Q | 10.3 | Fourth Amendment to Services Agreement, by and between Intrexon Corporation and Third Security, LLC, dated as of April 19, 2019. |
|---|
| 2019-05-09 | 10-Q | 10.2 | Form of Continuing Employment Agreement. |
|---|
| 2019-05-09 | 10-Q | 10.1 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective April 1, 2019. |
|---|
| 2019-03-01 | 10-K | 10.23 | Convertible Note issued to ARES TRADING S.A., dated December 28, 2018 |
|---|
| 2019-03-01 | 10-K | 10.22 | Securities Purchase, Assignment and Assumption Agreement, dated December 19, 2018, by and between Intrexon Corporation, ARES TRADING S.A. and Precigen, Inc. |
|---|
| 2018-11-08 | 10-Q | 10.1 | License Agreement, dated October 5, 2018, by and between Precigen, Inc. and ZIOPHARM Oncology, Inc. |
|---|
| 2018-07-03 | 8-K | 10.2 | Termination of Preferred Stock Equity Facility Agreement, dated June 28, 2018 |
|---|
| 2018-07-03 | 8-K | 10.1 | Share Lending Agreement, dated June 28, 2018 |
|---|
| 2018-06-08 | 8-K | 10.1 | Amendment to the Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, as amended, effective as of June 7, 2018. |
|---|
| 2018-04-05 | 8-K | 10.1 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of April 1, 2018. |
|---|
| 2018-03-01 | 10-K | 10.4A | Amendment No. 1 to the Exclusive Channel Collaboration Agreement between Intrexon and Oragenics, Inc. dated July 21, 2016 |
|---|
| 2018-03-01 | 10-K | 10.4B | Amendment No. 2 to the Exclusive Channel Collaboration Agreement between Intrexon and Oragenics, Inc. dated November 8, 2017 |
|---|
| 2018-03-01 | 10-K | 10.2K | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Form of Restricted Stock Unit Agreement for Officers |
|---|
| 2018-03-01 | 10-K | 10.2L | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Form of Restricted Stock Unit Agreement for Directors |
|---|
| 2018-01-02 | 8-K | 10.1 | Third Amendment to Services Agreement, by and between Intrexon Corporation and Third Security, LLC, effective as of January 1, 2018 |
|---|
| 2017-10-16 | 8-K | 10.1 | Preferred Stock Equity Facility Agreement, dated October 16, 2017 by and between Kapital Joe, LLC and Intrexon Corporation. |
|---|
| 2017-06-30 | 8-K | 10.1 | Amendment to the Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, as amended, effective as of June 28, 2017. |
|---|
| 2017-03-31 | 8-K | 10.1 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of April 1, 2017 |
|---|
| 2017-03-01 | 10-K | 10.3 | Exclusive Channel Partner Agreement, dated as of January 6, 2011, between Intrexon and ZIOPHARM Oncology, Inc., as amended |
|---|
| 2016-12-30 | 8-K | 10.2 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of January 1, 2017 |
|---|
| 2016-12-30 | 8-K | 10.1 | Second Amendment to Services Agreement, by and between Intrexon Corporation and Third Security, LLC, effective as of January 1, 2017 |
|---|
| 2016-11-03 | 8-K | 10.2 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of November 1, 2016 |
|---|
| 2016-11-03 | 8-K | 10.1 | First Amendment to Services Agreement, by and between Intrexon Corporation and Third Security, LLC, effective as of November 1, 2016 |
|---|
| 2016-08-09 | 10-Q | 10.5 | Employment Agreement, dated as of May 16, 2016, between Intrexon Corporation and Geno J. Germano. |
|---|
| 2016-08-08 | 8-K | 10.1 | Offer Letter, dated as of August 5, 2016 |
|---|
| 2016-06-30 | 8-K | 10.3 | Securities Issuance Agreement by and between ZIOPHARM Oncology, Inc. and Intrexon Corporation dated as of June 29, 2016 |
|---|
| 2016-06-30 | 8-K | 10.2 | Amendment to Exclusive Channel Collaboration Agreement by and between ZIOPHARM Oncology, Inc. and Intrexon Corporation dated as of June 29, 2016 |
|---|
| 2016-06-30 | 8-K | 10.1 | Third Amendment to Exclusive Channel Partner Agreement by and between Intrexon Corporation and ZIOPHARM Oncology, Inc. dated as of June 29, 2016 |
|---|
| 2016-06-13 | 8-K | 10.1 | Amendment to the Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, effective as of June 9, 2016. |
|---|
| 2015-11-03 | 8-K/A | 10.2 | Intrexon Corporation 2013 Amended and Restated Omnibus Incentive Plan, as amended, Restricted Stock Unit Agreement, by and between Intrexon Corporation and Randal J. Kirk, effective as of November 1, 2015 |
|---|
| 2015-11-03 | 8-K/A | 10.1 | Services Agreement, by and between Intrexon Corporation and Third Security, LLC, effective as of November 1, 2015 |
|---|
| 2015-06-17 | 8-K | 10.2 | Intrexon Corporation Annual Executive Incentive Plan, adopted as of April 29, 2015. |
|---|
| 2015-06-17 | 8-K | 10.1 | Amendment to the Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, effective as of June 11, 2015. |
|---|
| 2015-04-02 | 8-K | 10.2 | Second Amendment to Exclusive Channel Partner Agreement |
|---|
| 2015-04-02 | 8-K | 10.1 | License and Collaboration Agreement |
|---|
| 2015-01-28 | 8-K/A | 10.5 | License Agreement by and among ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, dated as of January 13, 2015 |
|---|
| 2015-01-14 | 8-K | 10.4 | Registration Rights Agreement by and among Intrexon Corporation, The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as of January 13, 2015 |
|---|
| 2015-01-14 | 8-K | 10.3 | Securities Issuance Agreement by and among Intrexon Corporation, The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as of January 13, 2015 (relating to the Incentive Shares) |
|---|
| 2015-01-14 | 8-K | 10.2 | Securities Issuance Agreement by and among Intrexon Corporation, The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center dated as of January 13, 2015 (relating to the License Shares) |
|---|
| 2015-01-14 | 8-K | 10.1 | Letter Agreement by and between ZIOPHARM Oncology, Inc., Intrexon Corporation and The University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, dated as of January 9, 2015 |
|---|
| 2014-06-13 | 8-K | 10.4 | Form of Nonqualified Stock Option Agreement. |
|---|
| 2014-06-13 | 8-K | 10.3 | Form of Incentive Stock Option Agreement. |
|---|
| 2014-06-13 | 8-K | 10.2 | Form of Restricted Stock Agreement. |
|---|
| 2014-06-13 | 8-K | 10.1 | Intrexon Corporation Amended and Restated 2013 Omnibus Incentive Plan, effective as of June 9, 2014. |
|---|
| 2014-04-04 | 8-K/A | 10.2 | Amended and Restated Limited Liability Company Agreement of Intrexon Energy Partners, LLC, dated as of March 26, 2014, by and among Intrexon Corporation and the parties thereto. |
|---|
| 2014-04-04 | 8-K/A | 10.1 | Exclusive Channel Collaboration Agreement, dated as of March 26, 2014, by and between Intrexon Corporation and Intrexon Energy Partners, LLC. |
|---|
| 2014-01-30 | 8-K | 10.1 | First Amendment to Agreement and Plan of Merger, dated as of January 29, 2014, by and among Intrexon Corporation, XON Cells, Inc. and Medistem Inc. |
|---|
| 2014-01-13 | 8-K | 10.2 | Supplemental Stock Issuance Agreement, dated as of January 10, 2014, between Intrexon and Fibrocell. |
|---|
| 2014-01-13 | 8-K | 10.1 | Second Amendment to Exclusive Channel Collaboration Agreement, dated as of January 10, 2014, between Intrexon and Fibrocell. |
|---|
| 2013-10-30 | 8-K/A | 10.2 | Limited Liability Company Agreement of S & I Ophthalmic, LLC, dated September 30, 2013, between Intrexon and Caraco Pharmaceutical Laboratories Ltd. |
|---|
| 2013-10-30 | 8-K/A | 10.1 | Exclusive Channel Collaboration Agreement, dated as of September 30, 2013, between Intrexon and S & I Ophthalmic, LLC. |
|---|
| 2013-10-01 | 8-K | 10.4 | Convertible Promissory Note, dated September 30, 2013. |
|---|
| 2013-10-01 | 8-K | 10.3 | First Amendment to the Stock Purchase and Issuance Agreement, dated as of September 30, 2013, by and between Intrexon Corporation and Oragenics, Inc. |
|---|
| 2013-10-01 | 8-K | 10.2 | Stock Purchase and Issuance Agreement, dated as of September 30, 2013, by and between Intrexon Corporation and Oragenics, Inc. |
|---|
| 2013-10-01 | 8-K | 10.1 | Exclusive Channel Collaboration Agreement, dated as of September 30, 2013, by and between Intrexon Corporation and Oragenics, Inc. |
|---|